• CX-5461: RNA Polymerase I Inhibitor Workflows

  2026-09-08

  CX-5461 provides a practical way to connect Pol I-driven rRNA synthesis with DNA damage, mitotic catastrophe, autophagy, and senescence assays. This workflow-focused guide covers formulation, dose-response design, cervical cancer combination studies, solid tumor models, and troubleshooting for reproducible cancer research.

• WEHI-539: Mapping BCL-XL Apoptotic Dependency

  2026-09-08

  Explore how WEHI-539, a selective BCL-XL inhibitor, can map mitochondrial apoptosis, distinguish BCL-XL from MCL-1 dependence, and improve cancer stem cell sensitization studies. This article translates mechanistic findings into practical assay decisions.

• Batimastat (BB-94) Experimental Workflows

  2026-09-07

  Batimastat (BB-94) provides a practical way to test how MMP-dependent proteolysis shapes tumor invasion, angiogenesis, and extracellular BDNF processing. This guide connects nanomolar enzyme assays with cell, neuromuscular-junction, and orthotopic colon cancer workflows while emphasizing controls, dosing logic, and troubleshooting.

• CXCR4, Autophagy, and EBV Latency in Gastric Cancer

  2026-09-07

  The reference study identifies CXCR4 as a mechanistic link between EBV latent signaling, autophagy, cell survival, and maintenance of EBV latency in EBV-associated gastric carcinoma. Its combined genomic, molecular, and cellular approach supports a model in which LMP2A activates an AKT–NRF1–CXCR4 axis, while CXCR4 regulates ZEB1–ATG7-dependent autophagy and suppresses lytic EBV activation.

• Colistin–Gamithromycin Synergy in Murine Pneumonia

  2026-09-05

  This study shows that colistin and gamithromycin can produce isolate-dependent synergy against Pasteurella multocida, including enhanced activity against strains with high colistin MICs. By integrating susceptibility testing, time-kill experiments, a neutropenic mouse pneumonia model, and PK/PD analysis, the work provides a preclinical framework for dose optimization and combination therapy against respiratory infection.

• Batimastat (BB-94) for MMP Assays and Models

  2026-09-04

  Batimastat (BB-94) gives researchers a broad-spectrum way to separate MMP-dependent proteolysis from direct cell toxicity in biochemical, cancer, and neuromuscular-junction experiments. This guide translates its zinc-chelating mechanism, defined potency, DMSO handling, and preclinical tumor activity into practical workflows with controls and troubleshooting strategies.

• Omeprazole A2845: Practical Research Workflow

  2026-09-04

  This practical guide explains how to use Omeprazole A2845 in controlled H+,K+-ATPase and gastric acid secretion research, with emphasis on solvent handling, assay controls, storage, and reproducibility. It is intended for scientific research and should not be used for diagnosis, treatment, or direct clinical interpretation.

• Bovine Insulin for Glioblastoma Assays

  2026-09-03

  Use Bovine Insulin to stabilize the metabolic and proliferative baseline of glioblastoma cell assays without confusing supplementation effects with delayed drug-induced death. This workflow pairs controlled insulin exposure with senescence-aware timing, vehicle controls, and practical troubleshooting for reproducible TMZ-response studies.

• AG-126: From ERK Biology to Translational Insight

  2026-09-03

  AG-126 (Tyrphostin AG-126) offers a focused pharmacological entry point for testing ERK1/2 involvement in inflammation while encouraging a disciplined bridge to neurobehavioral research. This article connects PCW-model evidence with striatal D2-MSN biology without overstating causality.

• PA-824: Bicyclic Nitroimidazole TB Research

  2026-09-02

  PA-824 is a bicyclic nitroimidazole derivative and tuberculosis research compound with activity against replicating and non-replicating Mycobacterium tuberculosis. Its reported mechanism combines ketomycolate-biosynthesis inhibition with nitroreduction-linked nitric oxide release, while recent evidence connects pretomanid to inhibition of both terminal respiratory oxidase branches.

• Anti-ROR1 Antibody: Workflow and Assay Guide

  2026-09-02

  Build a reproducible ROR1 binding, cell-surface phenotyping, and pathway-blockade workflow with Zilovertamab. The same unconjugated reagent can support cancer-focused assays and a carefully controlled exploratory extension into deoxynivalenol-induced liver injury research.

• Ceftazidime Workflows for Resistance Research

  2026-09-01

  Build reproducible Gram-negative susceptibility, selection, and transmission assays with Ceftazidime, a third-generation cephalosporin known for strong in vitro activity against Pseudomonas aeruginosa. This workflow also shows how to interpret ceftazidime phenotypes alongside plasmid localization, carbapenemase PCR, and conjugation data in resistant Enterobacter cloacae.

• Liproxstatin-1 HCl for Ferroptosis Assays

  2026-09-01

  Liproxstatin-1 HCl provides a selective ferroptosis-rescue arm for cell-based studies, helping distinguish lipid peroxidation from apoptosis or nonspecific oxidative injury. Its utility extends from GPX4- and RAS-related models to mechanistic studies of mitochondrial calcium signaling and disease-relevant injury workflows.

• Bradford Protein Assay Kit: Practical Workflow

  2026-08-31

  The Bradford Protein Assay Kit (SKU K4103) provides a rapid biochemical protein assay for estimating protein concentration from small liquid samples with Coomassie G-250 dye and BSA standards. It is suitable for routine enzyme, purification, and molecular biology workflows, but samples containing high detergent, strong chaotrope, or other dye-binding interference should be cleaned up or measured with a compatible alternative.

• Influenza HA Peptide: An Assay Decision Guide

  2026-08-31

  The Influenza Hemagglutinin (HA) Peptide is more than a detection reagent: it is a controllable competitive-elution tool for native protein workflows. This guide explains its mechanism, assay-design tradeoffs, and relevance to HA-tagged cancer biology studies.

8626 records 1/576 page Next 12345 下5页 Last page